Abstract 181P
Background
The 90-day mortality following lung cancer treatment is often included in sets of performance indicators to monitor quality of care. The aim of the current study was to investigate te 90-day mortality rate following curative intent radiotherapy in the Dutch lung cancer population and to evaluate the applicability of this parameter to monitor radiotherapy quality.
Methods
Data was extracted from the Netherlands National Cancer Registry for this retrospective population-based study on early mortality following curative intent (chemo)radiotherapy for clinical stage I-III lung cancer. Early mortality rates from the start and end of radiotherapy were compared. The association between several patient and tumor characteristics and 90-day mortality was evaluated with multivariable logistic regression analysis.
Results
A total of 18,355 patients treated between 2015-2020 were included. The 90-day mortality was 2.56% in stage I-II and 4.60% in stage III. Early mortality was significantly higher in males, elderly patients and patients with a poor performance status and was independent of facility volume. In stage I-II, 90-day mortality was lower after stereotactic versus conventional radiotherapy (2.0% versus 5.3%). In stage III, 90-day mortality decreased from 5.3% in 2015-2016 to 3.7% in 2019-2020 and was lower after concurrent versus sequential chemoradiotherapy (3.4% versus 5.9%). The mortality rate increased to 3.20% in stage I-II and 6.70% in stage III when calculated from the end of radiotherapy.
Conclusions
Short-term mortality rates following curative intent radiotherapy for lung cancer in the Netherlands are low and independent of facility volume. Standardization of definitions and relevant case-mix factors is needed to determine whether 90-day mortality could be useful to monitor the quality of radiotherapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. De Ruysscher: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Philips Health, BMS, AstraZeneca, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca, Varian; Financial Interests, Personal, Funding: Olink; Financial Interests, Institutional, Funding: BeiGene; Financial Interests, Institutional, Other, Advise group brain metastases NSCLC: Eli Lilly. All other authors have declared no conflicts of interest.